Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment
Cytomegalovirus (CMV) reactivation has been linked to adverse clinical outcomes in critically ill patients, with emerging evidence suggesting a potential connection with severe COVID-19. Mechanisms driving this association may include primary lung injury, amplification of systemic inflammation, and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/5/1165 |
| _version_ | 1797598130353471488 |
|---|---|
| author | Georgios Schinas Vasiliki Moustaka Eleni Polyzou Maria Panagiota Almyroudi George Dimopoulos Karolina Akinosoglou |
| author_facet | Georgios Schinas Vasiliki Moustaka Eleni Polyzou Maria Panagiota Almyroudi George Dimopoulos Karolina Akinosoglou |
| author_sort | Georgios Schinas |
| collection | DOAJ |
| description | Cytomegalovirus (CMV) reactivation has been linked to adverse clinical outcomes in critically ill patients, with emerging evidence suggesting a potential connection with severe COVID-19. Mechanisms driving this association may include primary lung injury, amplification of systemic inflammation, and secondary immunosuppression. Diagnostic challenges in detecting and assessing CMV reactivation necessitate a comprehensive approach to improve accuracy and inform treatment decisions. Currently, there is limited evidence on the efficacy and safety of CMV pharmacotherapy in critically ill COVID-19 patients. Although insights from non-COVID-19 critical illness studies suggest a potential role for antiviral treatment or prophylaxis, the risks and benefits must be carefully balanced in this vulnerable patient population. Understanding the pathophysiological role of CMV in the context of COVID-19 and exploring the advantages of antiviral treatment are crucial for optimizing care in critically ill patients. This review provides a comprehensive synthesis of available evidence, emphasizing the need for additional investigation to establish the role of CMV treatment or prophylaxis in the management of severe COVID-19 and to develop a framework for future research on this topic. |
| first_indexed | 2024-03-11T03:15:00Z |
| format | Article |
| id | doaj.art-fc185a35a5fe4c26b5984b80576396a5 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T03:15:00Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-fc185a35a5fe4c26b5984b80576396a52023-11-18T03:39:56ZengMDPI AGViruses1999-49152023-05-01155116510.3390/v15051165Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral TreatmentGeorgios Schinas0Vasiliki Moustaka1Eleni Polyzou2Maria Panagiota Almyroudi3George Dimopoulos4Karolina Akinosoglou5Medical School, University of Patras, 26504 Patras, GreeceMedical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMedical School, University of Patras, 26504 Patras, GreeceDepartment of Emergency Medicine, University Hospital ATTIKON, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece3rd Department of Critical Care, EVGENIDIO Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, GreeceMedical School, University of Patras, 26504 Patras, GreeceCytomegalovirus (CMV) reactivation has been linked to adverse clinical outcomes in critically ill patients, with emerging evidence suggesting a potential connection with severe COVID-19. Mechanisms driving this association may include primary lung injury, amplification of systemic inflammation, and secondary immunosuppression. Diagnostic challenges in detecting and assessing CMV reactivation necessitate a comprehensive approach to improve accuracy and inform treatment decisions. Currently, there is limited evidence on the efficacy and safety of CMV pharmacotherapy in critically ill COVID-19 patients. Although insights from non-COVID-19 critical illness studies suggest a potential role for antiviral treatment or prophylaxis, the risks and benefits must be carefully balanced in this vulnerable patient population. Understanding the pathophysiological role of CMV in the context of COVID-19 and exploring the advantages of antiviral treatment are crucial for optimizing care in critically ill patients. This review provides a comprehensive synthesis of available evidence, emphasizing the need for additional investigation to establish the role of CMV treatment or prophylaxis in the management of severe COVID-19 and to develop a framework for future research on this topic.https://www.mdpi.com/1999-4915/15/5/1165cytomegalovirus infectionsCOVID-19antiviral agentsintensive care unitsSARS-CoV-2CMV |
| spellingShingle | Georgios Schinas Vasiliki Moustaka Eleni Polyzou Maria Panagiota Almyroudi George Dimopoulos Karolina Akinosoglou Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment Viruses cytomegalovirus infections COVID-19 antiviral agents intensive care units SARS-CoV-2 CMV |
| title | Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment |
| title_full | Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment |
| title_fullStr | Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment |
| title_full_unstemmed | Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment |
| title_short | Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment |
| title_sort | targeting cmv reactivation to optimize care for critically ill covid 19 patients a review on the therapeutic potential of antiviral treatment |
| topic | cytomegalovirus infections COVID-19 antiviral agents intensive care units SARS-CoV-2 CMV |
| url | https://www.mdpi.com/1999-4915/15/5/1165 |
| work_keys_str_mv | AT georgiosschinas targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment AT vasilikimoustaka targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment AT elenipolyzou targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment AT mariapanagiotaalmyroudi targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment AT georgedimopoulos targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment AT karolinaakinosoglou targetingcmvreactivationtooptimizecareforcriticallyillcovid19patientsareviewonthetherapeuticpotentialofantiviraltreatment |